



PRIOR AUTHORIZATION REQUEST

SIMPONI SQ

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL PA requests**. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

- | | | | |
|---|---|-----|----|
| 1 | Is this request for initial therapy or for continuation of therapy? | | |
| | ☐ Initial (If checked, go to 8) | | |
| | ☐ Continuation (If checked, go to 2) | | |
| 2 | Will the patient be using the requested medication in combination with other biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs)?
[Note: Examples of biologic DMARDs include adalimumab SC products (Humira, | Yes | No |

If you have any
questions, call:
1-888-258-8250

Version 06.2026

PRIOR AUTHORIZATION REQUEST

biosimilars), Cimzia, etanercept SC products (Enbrel, biosimilars), infliximab IV products (Remicade, biosimilars), Actemra (IV or SC), Simponi Aria (IV), Kevzara, Orencia (IV or SC), rituximab IV products (Rituxan, biosimilars), Ilaris, Kineret, Stelara (SC or IV), Siliq, Cosentyx, Taltz, Ilumya, Skyrizi, Tremfya, and Entyvio. Examples of targeted synthetic DMARDs include Otezla, Olumiant, Rinvoq, and Xeljanz/XR.]

[If yes, no further questions.]

- | | | | |
|---|---|-----|----|
| 3 | Is the patient currently receiving the requested medication?
[If no, skip to question 8.] | Yes | No |
| 4 | Has the patient been receiving medication samples for the requested medication?
[If yes, skip to question 8.] | Yes | No |
| 5 | Does the patient have a previously approved PA on file with the current plan?
[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]
[If no, skip to question 8.] | Yes | No |
| 6 | Has the patient been on established therapy for at least 3 months?
[If no, skip to question 8.] | Yes | No |
| 7 | Has documentation been submitted to confirm that the patient has had a clinically significant response to therapy, as determined by the prescriber? ACTION REQUIRED: Submit supporting documentation.
[No further questions.] | Yes | No |
| 8 | Will the patient be using the requested medication in combination with other biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs)?
[Note: Examples of biologic DMARDs include adalimumab SC products (Humira, biosimilars), Cimzia, etanercept SC products (Enbrel, biosimilars), infliximab IV products (Remicade, biosimilars), Actemra (IV or SC), Simponi Aria (IV), Kevzara, Orencia (IV or SC), rituximab IV products (Rituxan, biosimilars), Ilaris, Kineret, Stelara (SC or IV), Siliq, Cosentyx, Taltz, Ilumya, Skyrizi, Tremfya, and Entyvio. Examples of targeted synthetic DMARDs include Otezla, Olumiant, Rinvoq, and Xeljanz/XR.]
[If yes, no further questions.] | Yes | No |
| 9 | What is the diagnosis or indication?

☐ Rheumatoid arthritis (If checked, go to 10)

☐ Psoriatic arthritis (PsA) (If checked, go to 17)

☐ Ankylosing spondylitis (AS) (If checked, go to 25)

☐ Ulcerative colitis (UC) (If checked, go to 31) | | |

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026

PRIOR AUTHORIZATION REQUEST

☐ Spondyloarthritis (SpA), other subtypes (for example, undifferentiated arthritis, non-radiographic axial SpA, reactive arthritis [Reiter's disease]) [Note: For AS or PsA, refer to the respective criteria.] (If checked, go to 42)

☐ Plaque psoriasis without psoriatic arthritis (If checked, no further questions)

☐ Other (If checked, no further questions)

10	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
11	Has the patient tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for at least 3 months? [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If yes, skip to question 13.]	Yes	No
12	Has documentation been submitted to confirm that the patient has had an intolerance to at least TWO conventional synthetic disease-modifying antirheumatic drugs? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If no, no further questions.]	Yes	No
13	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with a preferred adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
14	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
15	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [If no, no further questions.]	Yes	No
16	Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved labeled dosing for the indication? [Note: Dosing is 50 mg subQ once monthly.] [No further questions.]	Yes	No
17	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026

PRIOR AUTHORIZATION REQUEST

18	Has the patient tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for at least 3 months? [Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If yes, skip to question 20.]	Yes	No
19	Has documentation been submitted to confirm that the patient has had an intolerance or contraindication to at least TWO conventional synthetic disease-modifying antirheumatic drugs? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.] [If no, no further questions.]	Yes	No
20	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with a preferred adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
21	Has documentation been submitted to confirm that the patient has had a treatment failure with a preferred ustekinumab product (Pyzchiva, Stegeyma, and Yesintek) for at least 3 months or is the patient intolerant, or the medication contraindicated? ACTION REQUIRED: Submit support documentation. [If no, no further questions.]	Yes	No
22	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
23	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [If no, no further questions.]	Yes	No
24	Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved labeled dosing for the indication? [Note: Dosing is 50 mg subQ once monthly.] [No further questions.]	Yes	No
25	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
26	Does the patient have a diagnosis of active ankylosing spondylitis? [If no, no further questions.]	Yes	No
27	Has documentation been submitted to confirm that the patient has an intolerance,	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026

PRIOR AUTHORIZATION REQUEST

contraindication to, or failed treatment for at least 3 months with a preferred adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)?

ACTION REQUIRED: Submit supporting documentation.

[If no, no further questions.]

- | | | | |
|----|--|-----|----|
| 28 | Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions.] | Yes | No |
| 29 | Is the requested medication being prescribed by, or in consultation with, a rheumatologist?
[If no, no further questions.] | Yes | No |
| 30 | Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved labeled dosing for the indication?
[Note: Dosing is 50 mg subQ once monthly.]
[No further questions.] | Yes | No |
| 31 | Is the patient's weight greater than or equal to 15 kg?
[If no, no further questions.] | Yes | No |
| 32 | Is the patient diagnosed with moderately to severely active ulcerative colitis?
[If no, no further questions.] | Yes | No |
| 33 | Has the patient had a trial of at least TWO traditional systemic therapy agents for at least 3 months?
[Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone.]
[If yes, skip to question 35.] | Yes | No |
| 34 | Has documentation been submitted to confirm that the patient has an intolerance to or contraindication to at least TWO traditional systemic therapy agents?
ACTION REQUIRED: Submit supporting documentation.
[Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone.]
[If no, no further questions.] | Yes | No |
| 35 | Does the patient have pouchitis?
[If no, skip to question 37.] | Yes | No |
| 36 | Has the patient tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine) enema?
[Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticosteroid enema include hydrocortisone enema (Cortenema, generics).]
[If no, no further questions.] | Yes | No |
| 37 | Has documentation been submitted to confirm that the patient has an intolerance, | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026

PRIOR AUTHORIZATION REQUEST

contraindication to, or failed treatment for at least 3 months with a preferred adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)?

ACTION REQUIRED: Submit supporting documentation.

[If no, no further questions.]

- | | | | |
|-----------|---|-----|----|
| 38 | Has documentation been submitted to confirm that the patient has had a treatment failure with a preferred ustekinumab product (Pyzchiva, Steqeyma, or Yesintek) for at least 3 months or is the patient intolerant or the medication contraindicated?
ACTION REQUIRED: Submit support documentation.
[If no, no further questions.] | Yes | No |
| 39 | Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation.
[If no, no further questions.] | Yes | No |
| 40 | Is the requested medication prescribed by, or in consultation with, a gastroenterologist?
[If no, no further questions.] | Yes | No |
| 41 | Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved labeled dosing for the indication?
[Note: Dosing is 100 mg SUBQ at week 0 followed by maintenance dosage of 50 mg starting at week 2 and every 4 weeks thereafter for a patient weighing 15kg to less than 40 kg OR 200 mg SUBQ at week 0 followed by maintenance dosage of 100 mg starting at week 2 and every 4 weeks thereafter for a patient weighing 40 kg or greater.]
[No further questions.] | Yes | No |
| 42 | Is the patient greater than or equal to 18 years of age?
[If no, no further questions.] | Yes | No |
| 43 | Is the patient diagnosed with Spondyloarthritis (SpA)?
[If no, no further questions.] | Yes | No |
| 44 | Has the patient tried at least TWO conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for at least 3 months?
[Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.]
[If yes, skip to question 46.] | Yes | No |
| 45 | Has documentation been submitted to confirm that the patient has an intolerance to at least TWO conventional synthetic disease-modifying antirheumatic drugs (DMARDs)? ACTION REQUIRED: Submit supporting documentation.
[Note: Examples of conventional synthetic DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine.]
[If no, no further questions.] | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026



PRIOR AUTHORIZATION REQUEST

46	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with a preferred adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
47	Is the requested medication being prescribed by, or in consultation with, a rheumatologist? [If no, no further questions.]	Yes	No
48	Does the dose of the requested medication exceed Food and Drug Administration (FDA) approved labeled dosing for the indication? [Note: Dosing is 50 mg subQ once monthly.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any
questions, call:
1-888-258-8250**

Version 06.2026